Invesco Ltd. Cerevel Therapeutics Holdings, Inc. Transaction History

Invesco Ltd.

$460 Billion
Q2 2024

A detailed history of Invesco Ltd. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 57,337 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,337

Previous 39,344 45.73%

Holding current value

Previous $1.66 Million 40.95%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.96 - $42.75 $701,007 - $769,200	17,993 Added 45.73%	57,337 $2.34 Million
Q1 2024 May 14, 2024	BUY	$40.88 - $43.27 $360,970 - $382,074	8,830 Added 28.94%	39,344 $1.66 Million
Q4 2023 Feb 12, 2024	SELL	$20.27 - $42.44 $30,283 - $63,405	-1,494 Reduced 4.67%	30,514 $1.29 Million
Q3 2023 Nov 13, 2023	SELL	$20.26 - $31.91 $7,415 - $11,679	-366 Reduced 1.13%	32,008 $698,000
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $10,946 - $16,204	458 Added 1.44%	32,374 $1.03 Million
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $28,821 - $44,609	1,263 Added 4.12%	31,916 $778,000
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $199,631 - $251,685	7,875 Added 34.57%	30,653 $966,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $42,177 - $68,508	1,654 Added 7.83%	22,778 $643,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $76,788 - $138,346	3,724 Added 21.4%	21,124 $558,000
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $8,084 - $12,170	-344 Reduced 1.94%	17,400 $610,000
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $9.85 Million - $15.1 Million	-337,144 Reduced 95.0%	17,744 $575,000
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $7.28 Million - $13.3 Million	342,534 Added 2772.66%	354,888 $10.5 Million
Q2 2021 Aug 17, 2021	BUY	$12.56 - $29.69 $155,166 - $366,790	12,354 New	12,354 $317,000

Others Institutions Holding CERE

# of Institutions

207

Shares Held

149M

Call Options Held

2.19M

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account